Development of a screen to identify selective small molecules active against patient-derived metastatic and chemoresistant breast cancer cells.

Abstract excerpt

INTRODUCTION: High failure rates of new investigational drugs have impaired the development of breast cancer therapies. One challenge is that excellent activity in preclinical models, such as established cancer cell lines, does not always translate into improved clinical outcomes for patients. New preclinical models, which better replicate clinically-relevant attributes of cancer, such as chemoresistance,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Caspases
• Share to Cell Death